联合手术治疗合并白内障的玻璃体视网膜病变

目的:探讨玻璃体视网膜病变合并白内障患者的玻璃体手术中,同期行白内障超声乳化摘除术的临床效果。方法:回顾性分析合并有白内障的玻璃体视网膜病变患者37例(40眼),实施玻璃体切割联合晶状体超声乳化人工晶状体植入手术,观察术后视力改善程度及术中术后并发症。结果:术后随访3~24mo,其中29眼(72%)视力有不同程度的改善,不变8眼(20%),下降3眼(8%);术后视力低下者主要原因为黄斑病变。结论:玻璃体切割联合晶状体超声乳化术治疗合并不同程度白内障玻璃体视网膜病变是安全有效的,可使患者视力改善,避免玻璃体切除术后并发白内障再次手术。     

玻璃体切割联合超声乳化人工晶状体植入术治疗PDR

目的:探讨采用玻璃体切割联合白内障超声乳化及后房型人工晶状体植入术治疗增生性糖尿病视网膜病变(proliferative diabetic retinopathy,PDR)合并白内障患者的临床效果。方法:对36例36眼合并白内障的增生性糖尿病视网膜病变患者行玻璃体切除联合白内障超声乳化人工晶状体植入手术,其中气体填充6眼,硅油填充4眼;观察术后视力改善程度及术中术后并发症。结果:手术后患者随访1~12(平均4.5)mo。术后36眼视力均有不同程度的改善,术后视力≥0.1有6眼(17%);0.02≤视力<0.1有24眼(67%),光感至数指有6眼(17%)。术中未发生严重的并发症。早期高眼压5眼(14%),虹膜后粘连3眼(8%),因后发性白内障行YAG激光后囊膜光切术12眼(33%)。1眼于术后1mo出现新生血管性青光眼(3%)。除高眼压患者,术后无明显角膜水肿或角膜内皮失代偿。术后未发生视网膜脱离和玻璃体出血。结论:玻璃体切除联合白内障超声乳化人工晶状体植入术治疗增生性糖尿病视网膜病变合并白内障患者是安全有效的。     

晶状体超声乳化吸出玻璃体切除治疗合并白内障的玻璃体视网膜病变的效果评价

目的探讨玻璃体视网膜病变合并白内障的玻璃体手术中,同期行超声乳化白内障吸出术的效果及并发症。方法回顾性分析合并有白内障的玻璃体视网膜病变30例（30眼）。实行玻璃体切除联合超声乳化吸出人工晶状体植入术观察术后视力改善情况及术中术后并发症。结果术后随访3～24个月,25眼（83.33%）术后均有不同程度视力改善,视力不变者3眼,视力下降者2眼。影响视力提高的主要原因为不同类型的黄斑病变。并发症主要有角膜水肿、一过性高眼压、术后炎症反应、后囊浑浊,均可治愈。结论超声乳化白内障吸出玻璃体切除联合术治疗合并不同程度白内障的玻璃体视网膜病变是安全有效的方法,它有利于患者视力改善,避免玻璃体切除术后并发白内障再次手术。玻璃体切除联合白内障手术不会明显增加手术并发症。     

超声乳化术治疗玻璃体切割术后并发性白内障的疗效观察

目的:探讨超声乳化术治疗玻璃体切割术后并发性白内障的手术特点、安全性及临床疗效。方法:对39例39眼玻璃体切割术后并发性白内障的患者行超声乳化术,其中对有硅油充填的23眼联合硅油取出术,观察手术前后视力及术中、术后并发症。术后随访3~24(平均10)mo。结果:所有病例术中无严重并发症发生。术后最佳矫正视力37眼(95%)提高,2眼(5%)无改变,无视力下降者。1眼硅油取出后2wk视网膜脱离复发,1眼术后1mo玻璃体出血,均行玻璃体切割联合硅油填充术而治愈。无脉络膜出血、低眼压等并发症。结论:玻璃体切割术后并发性白内障眼内情况复杂,手术难度大,超声乳化术是一种安全有效的手术方法。     

双微创玻璃体手术联合白内障人工晶状体植入的临床效果

目的:观察23G微创玻璃体切割联合1.8mm微切口白内障超声乳化并Ⅰ期植入人工晶状体(IOL)手术的临床效果.方法:回顾性分析2014-09/2015-03在我院行微创玻璃体切割联合微切口白内障超声乳化并Ⅰ期植入IOL手术者共48例54眼.术前、术后5d,1、3mo记录最佳矫正视力(best corrected visual acuity,BCVA)、眼压、角膜散光、角膜内皮细胞计数,观察眼底情况、IOL位置以及术后低眼压、角膜水肿、后发性白内障、高眼压等并发症.结果:所有患者手术均顺利完成.术后3mo BCVA较术前提高49眼(91％),视力无改善5眼(9％),无视力较术前下降者.手术前后眼压、角膜内皮细胞计数差异有显著统计学差异(P＜0.01),术后3 mo角膜内皮细胞丢失率为11.71％±8.12％.角膜散光术后早期增加(P＜0.05),术后3mo与术前无统计学差异(P＞0.05).术后发生一过性高眼压(术后1 mo内眼压＞25mmHg)者6眼,早期角膜水肿发生7眼,前房有成形渗出2眼,发生后囊膜混浊3眼,其中2眼行YAG激光后囊截开术,视力明显提高.术后眼底视网膜均平伏,无发生视网膜脱离、脉络膜脱离、感染性眼内炎、新生血管性青光眼、低眼压患者,无并发IOL偏位、脱位病例.结论:微创玻璃体切割联合微切口白内障超声乳化并Ⅰ期植入IOL手术适应证广泛、损伤小、恢复快、并发症少,是一种安全有效的手术方式,值得推广和应用.     

白内障超声乳化联合玻璃体切割术治疗增生性糖尿病视网膜病变

目的 探讨白内障超声乳化联合玻璃体切割术治疗增生性糖尿病视网膜病变(proliferate diabetic retinopathy,PDR)的疗效。方法 选取2009年10月至2014年5月在我科住院并行白内障超声乳化联合玻璃体切割术的PDR患者56例(75眼),术后随访6~60(28.24±5.47)个月。观察术后最佳矫正视力、眼压及并发症等情况。结果 全部患者手术均顺利完成,术后视力提高者70眼(93.33%),视力不变者3眼(4.00%),视力下降者2眼(2.67%)。术后1个月、3个月及末次随访时眼压分别为(20.3±9.2)mmHg(1 kPa=7.5 mmHg)、(17.1±7.3)mmHg、(19.2±8.5)mmHg,与术前的(12.7±6.1)mmHg相比,差异均有统计学意义(均为P<0.05)。术后主要并发症包括后囊膜混浊8眼,角膜轻度水肿5眼,前房渗出5眼,玻璃体再出血2眼,视网膜脱离2眼,新生血管性青光眼2眼。结论 白内障超声乳化联合玻璃体切割术治疗PDR安全有效,术后视力提高较明显,并发症发生率较低,值得在临床工作中推广应用。     

23G玻璃体切割手术联合超声乳化白内障摘除术对白内障并玻璃体视网膜病变患者视力及眼压变化的影响

目的观察23G玻璃体切割手术下玻璃体切割术(PPV)联合白内障超声乳化术治疗白内障并玻璃体视网膜病变的临床疗效。方法使用随机数表法将2017年1月至2018年12月在我院就诊的90例白内障并玻璃体视网膜病变患者分为对照组(n=45)和观察组(n=45)。对照组接受常规PPV联合白内障超声乳化术治疗,观察组接受23G玻璃体切割手术下PPV联合白内障超声乳化术治疗。对比两组术前、术后1个月和术后6个月时的最佳矫正视力(LogMAR视力)和眼压水平;统计两组术后并发症发生率。结果观察组术后1个月、6个月时的最佳矫正视力(LogMAR视力)低于对照组(P<0.05);观察组术后1个月、6个月时的眼压水平低于对照组(P<0.05);观察组术后并发症发生率(6.67%)低于对照组(22.22%),差异有统计学意义(P<0.05)。结论 23G玻璃体切割手术联合白内障超声乳化术治疗白内障并玻璃体视网膜病变临床疗效好于常规手术,有利于最佳矫正视力及眼压水平恢复正常,且能减少并发症的发生率,具有临床推广价值。     

不同联合手术方式治疗增生性糖尿病视网膜病变的有效性及并发症

目的:评价不同的联合手术方式治疗增生性糖尿病视网膜病变患者的有效性及并发症.方法:回顾性分析PDR患者72例82眼的临床资料.根据手术联合方式不同,分为A组28眼,行玻璃体切割术,同期联合白内障超声乳化术及人工晶状体植入术;B组24眼,行玻璃体腔注射康柏西普及玻璃体切割术,同期联合白内障超声乳化术及人工晶状体植入术;C组30眼,Ⅰ期行玻璃体切割术,Ⅱ期行硅油取出联合白内障超声乳化术及人工晶状体植入术.观察3组术后最佳矫正视力(BCVA)及并发症情况.结果:术后随访6~12mo.A组、B组、C组的术后平均LogMAR BCVA分别为1.007±0.455、1.000±0.482、1.033±0.531,3组较术前均有较明显的提高,差异有统计学意义(t=5.666、5.113、5.496,P<0.05).A组、B组和C组的术后BCVA比较,差异无统计学意义(F=1.670,P=0.195).术后并发症:A组发生前房渗出性反应6眼,一过性高眼压5眼,黄斑水肿1眼,新生血管性青光眼2眼,玻璃体再出血2眼;B组发生一过性高眼压4眼,玻璃体再出血1眼.C组发生前房渗出性反应1眼,一过性高眼压10眼,玻璃体再出血3眼.3组间前房渗出性反应的发生率差异有统计学意义(χ2=7.556,P=0.008),A组与B组两两比较,差异有统计学意义(χ2=5.814,P=0.016);A组与C组两两比较,差异无统计学意义(χ2=4.469,P=0.035).其他并发症的发生率在3组间差异均无统计意义(P>0.05).结论:两种联合方式均可较早恢复患者视力,避免再次行白内障手术.同期联合方式与二期联合方式相比,术中观察眼底清晰,便于后节操作;同期联合方式前房渗出性反应较重,玻璃体腔注射康柏西普能减轻同期联合方式的前房渗出性反应.     

玻璃体切割联合白内障超声乳化及IOL植入术中运用飞秒激光的临床研究

目的：分析玻璃体切割联合白内障超声乳化及人工晶状体(IOL)植入术中应用飞秒激光的临床价值。
　　方法：收集2013-10-31/2015-10-31在我院就诊需行玻璃体切割联合白内障超声乳化及 IOL 植入术的患者100例102眼,分为两组：常规手术组50例52眼和飞秒激光组50例50眼。比较两组患者总的手术时间、术后并发症(眼压升高、葡萄膜炎、玻璃体出血、视网膜脱离),比较术后6mo 的眼压、近视力、远视力、裸眼视力、矫正视力。
　　结果：两组患者总的手术时间有统计学差异(P<0.05),两组患者术后眼压升高、葡萄膜炎、玻璃体出血、视网膜脱离差异均无统计学意义(P>0.05);术后6mo 眼压、近视力、远视力、裸眼视力、矫正视力比较,差异均无统计学意义(P>0.05)。
　　结论：飞秒激光辅助的玻璃体切割联合白内障超声乳化及 IOL 植入术同常规手术一样,有较高的安全性和疗效,且具有精确、高效等优点。     

双微联合手术治疗合并白内障玻璃体视网膜疾病的疗效

目的:研究2mm微切口白内障超声乳化联合23G微创玻璃体切割手术治疗合并白内障玻璃体视网膜疾病的临床疗效.方法:回顾性分析2013-02/2016-02在本院接受治疗的合并白内障玻璃体视网膜疾病的患者92例99眼的临床基本资料,其中男49例53眼,女43例46眼,平均年龄57.1±1.9岁;患者进行眼球麻醉后行玻璃体切割术结合白内障的超声乳化;观察患者的手术疗效和术中、术后出现的并发症情况.结果:患者联合手术均进行得比较顺利,手术中没有后囊膜发生破裂的患者出现.患者中有7眼使用BSS液进行填充,有46眼注射入硅油,有46眼注射入C3F8;有49眼Ⅰ期时放置人工晶状体,有21眼在取出硅油时Ⅱ期放置人工晶状体;患者手术以后视力得到提升的有84眼(85%),视力没有发生变化的有15眼(15%);患者手术后出现的并发症包含一过性高眼压18眼(18%)、前房反应7眼(7%)和角膜水肿8眼(8%).结论:2mm微切口白内障超声乳化联合23G微创玻璃体切割手术对患者的创伤小、并发症少,是一种安全有效的手术方式.     

Pars plana vitrectomy, phacoemulsification and intraocular lens implantation. Comparison of clinical complications in a combined versus two-step surgical approach

Purpose To report intra-and postoperative complications in pars plana vitrectomy, phacoemulsification and intraocular lens implantation. A comparison of the combined versus two step surgical approach is given.Method Medical records and operative notes of 111 eyes with combined surgery and 50 eyes with sequential surgery were retrospectively analysed. Subgroup analysis was performed to evaluate differences in disease groups, the use of endotamponading or endolaser and cryocoagulation. Postoperative follow-up time was between 3 and 18 months.Results Combined surgery: 64 eyes (57.5%) showed no complications. 17 eyes (15.3%) showed transient intraocular pressure rise, 17 eyes (15.3%) fibrinous exudation in the anterior chamber. Posterior capsule tears occurred in 7 eyes (6,3%), formation of posterior synechia was observed in 7 eyes (6.3%). IOL dislocation was seen in 3 eyes (2.7%), heavy covering of macrophages in 3 eyes (2,7%). Rare complications included silicon oil efflux into the anterior chamber (1.8%), anterior chamber hemorrhage (1,8%) and iris incarceration into the corneoscleral incision (0,9%). One eye needed explantation of the IOL during the follow-up. Sequential surgery: 31 eyes (62%) showed no complication. Transient intraocular pressure rise occurred in 14 eyes (28%), fibrinous exudation in 2 eyes (4%). Formation of posterior synechia was observed in 1 eye (2%), posterior capsule tears occurred in 4 eyes (8%). Dislocation of the IOL was seen in 1 eye (2%). Subgroup analysis revealed fibrinous exudation in the anterior chamber to be significantly more frequent after combined surgery, particularly in cases of proliferative diabetic retinopathy.Conclusion Combined pars plana vitrectomy, phacoemulsification and intraocular lens implantation as well as the two-step procedure are safe and effective. Sequential surgery could be advantageous to minimize the postoperative anterior chamber inflammatory response.     

Cool phaco in combined phacoemulsification and vitrectomy surgery

PURPOSE: The aim of this paper is to present the use of bimanual phacoemulsification technique in combined phacoemulsification and vitrectomy surgery. MATERIAL AND METHODS: Combined phacoemulsification and vitrectomy procedure was performed in 20 eyes. Phacoemulsification was performed through two paracenteses. Soft acrylic intraocular lenses were implanted into the capsular bag through a paracentesis 1.8 mm wide. Standard three-port pars plana vitrectomy followed. Indications for vitrectomy were diabetic retinopathy, retina detachment, uveitis, macula hole. All surgeries were performed as one-day surgeries. Follow-up lasted six months. RESULTS: Visual acuity improved in 19/20 eyes (95%). The achieved functional results were similar to that achieved in standard phacoemulsification combined with vitreoretinal surgery. Surgery time did not differ significantly from time needed to perform a standard procedure. The bimanual technique allowed the stablization of the anterior chamber during vitreoretinal surgery. No serious postoperative complications occurred. CONCLUSIONS: The presented method improves the quality of combined surgery, ensures stability of the anterior chamber, reduces postoperative astigmatism, lowers the risk of inflammation.     

Surgical results of combined pars plana vitrectomy, phacoemulsification, and intraocular lens implantation

PURPOSE: To evaluate the results and complications of combined pars plana vitrectomy (PPV), phacoemulsification and aspiration (PEA), and intraocular lens (IOL) implantation. METHODS: A total of 117 eyes from 114 patients who had undergone PPV combined with PEA and IOL implantation were retrospectively analyzed. Combined surgery was performed for a wide variety of vitreoretinal diseases. Intraoperative and postoperative complications were also reviewed. RESULTS: The postoperative BCVA improved by 2 lines or more in 85 eyes (72.6%). Intraoperative complications consisted of retinal tears in 14 eyes (12.0%) and posterior capsular rupture in 2 eyes (1.7%). Iatrogenic retinal tears occurred more frequently in eyes with a macular hole than in eyes with any other disease (p=0.005, chi-square test). Postoperative complications consisted of posterior capsule opacification (PCO) (21 eyes), transient IOP elevation (29 eyes), vitreous hemorrhage (6 eyes), anterior chamber fibrin exudation (11 eyes), posterior iris synechia (8 eyes), neovascular glaucoma (1 eye), and recurrent retinal detachment (RD) (2 eyes). Fibrin exudation occurred more frequently in eyes with proliferative diabetic retinopathy (PDR) and RD than in eyes with any other disease (p=0.03, chi-square test). PCO occurred more frequently in eyes with PDR than in eyes with any other disease (p=0.03, chi-square test). CONCLUSIONS: The present study suggests that a high success rate can be achieved when recently improved PPV techniques are combined wi th PEA and IOL implantation. The complications that were observed following this combined treatment varied with respect to the vitreoretinal disease present prior to surgery.     

Combined surgery and sequential surgery comprising phacoemulsification,pars plana vitrectomy,and intraocular lens implantation: comparison of clinical outcomes

PURPOSE: To evaluate the effectiveness and safety of combined phacoemulsification, pars plana vitrectomy (PPV), and intraocular lens (IOL) implantation in diabetic and nondiabetic patients and compare the clinical results with those of sequential surgery. SETTING: Seoul National University College of Medicine, Seoul, South Korea. METHODS: The results of combined phacoemulsification, PPV, and IOL implantation in 52 patients (52 eyes) were retrospectively analyzed. The main outcome measures were preoperative and postoperative best corrected visual acuity (BCVA), postoperative BCVA of 20/40 or better, and intraoperative and postoperative complications. Combined surgery and sequential surgery were also compared using the same outcome measures. RESULTS: Postoperatively, the BCVA was better in 44 eyes (84.6%); 12 eyes (23.1%) achieved a BCVA of 20/40 or better. Postoperative complications consisted of a transient intraocular pressure increase in 29 eyes (55.8%), hyphema in 10 (19.2%), neovascular glaucoma in 8 (15.4%), anterior chamber fibrin exudation in 7 (13.5%), vitreous hemorrhage in 7 (13.5%), retinal detachment in 3 (5.8%), and posterior capsule opacification in 1 (1.9%). In the diabetic patients, postoperative visual outcomes between the combined-surgery group and the sequential-surgery group were not significantly different; however, neovascular glaucoma occurred only in the combined-surgery group. Other complications were not different between the combined-surgery group and the sequential-surgery group. In the nondiabetic patients, the postoperative visual outcomes and complications between the 2 groups were not significantly different. CONCLUSIONS: Combined phacoemulsification, PPV, and IOL implantation was safe and effective in selected patients, with the clinical outcomes comparable to those of sequential surgery.     

Clinical outcomes of 25-gauge vitrectomy surgery for vitreoretinal diseases: comparison of vitrectomy alone and phaco-vitrectomy

AIM: To compare the clinical outcomes of combined 25-gauge pars plana vitrectomy (PPV) and phacoemulsification/posterior chamber intraocular lens (PC-IOL) implantation with vitrectomy alone surgery in patients with various vitreoretinal diseases. METHODS: A total of 306 eyes (145 with PPV alone and 161 with phaco-vitrectomy) were enrolled in this retrospective analysis. The surgical approach was 25-gauge PPV combined with phacoemulsification and PC-IOL implantation at the same time in eyes in phaco-vitrectomy group and only PPV in eyes in vitrectomy alone surgery group. The main outcome measures were postoperative clinical outcomes included anterior chamber inflammation, changes in intraocular pressure (IOP) and best corrected visual acuity (BCVA). RESULTS: The most common postoperative complication was anterior chamber reaction which has higher incidence in phaco-vitrectomy group (P<0.001). The mean postoperative 1st day IOP of vitrectomy alone group was significantly lower than that of phaco-vitrectomy group (16.3±5.8 mm Hg vs 17.8±8.1 mm Hg, respectively, P=0.02). Hypotony (IOP(8 mm Hg) was not different between groups in the postoperative 1st day (P>0.05). The mean preoperative visual acuity was not different between groups (1.6±0.9 logMAR vs 1.8±0.9 logMAR, respectively, P>0.05). However, the mean visual acuity was decreased in vitrectomy alone group at the final visit compared to phaco-vitrectomy group (1.2±0.8 logMAR, 0.9±0.7 logMAR, respectively P<0.05). CONCLUSION: Twenty-five gauge PPV combined with phacoemulsification surgery is a safe and efficient procedure, which can be preferred in phacic patients with a variety of vitreoretinal diseases compared to vitrectomy alone. Despite improved outcomes, this approach is not free of limitations as anterior chamber complications especially with combined surgery.     

Sutureless combined 25-gauge vitrectomy, phacoemulsification, and posterior chamber intraocular lens implantation for management of uveitic cataract associated with posterior segment disease

PURPOSE: To report visual outcomes and complication rates associated with one-stage surgery for the management of uveitic cataract associated with posterior segment disease. METHODS: In this interventional case series, 19 eyes (19 patients) with posterior segment involvement due to chronic uveitis underwent sutureless scleral tunnel incision phacoemulsification combined with total vitrectomy using 25-gauge instruments and posterior chamber intraocular lens (PC-IOL) implantation. Membrane peeling and endolaser photocoagulation were performed when indicated. Outcome measures were visual acuity, inflammatory activity, macular edema, and complications of surgery. RESULTS: After a minimum 12-month follow-up, visual acuity was >or=20/100 in 12 eyes (63.2%); 6 eyes (31.6%) had visual acuity of >or=20/40. A decrease in postoperative inflammatory activity of 1 grade was observed in 8 eyes (42.1%). Sixteen eyes had cystoid macular edema before surgery; and 12 eyes had cystoid macular edema after surgery. Early postoperative complications included the following: transient corneal edema, 10 eyes (50.3%); fibrin reaction, 3 eyes (15.8%), and posterior synechiae, 9 eyes (47.3%). Glaucoma was the most common late postoperative complication (3 eyes [18.8%]). Nine eyes (47.4%) needed YAG laser capsulotomy during the first year. CONCLUSION: Sutureless combined 25-gauge total vitrectomy, phacoemulsification, and PC-IOL implantation may be well tolerated with an acceptable complication rate for selected uveitic eyes with significant cataract and coexisting posterior segment disease for restoring useful vision.     

玻璃体切割联合视网膜睫状体光凝术与内窥镜睫状体光凝术治疗新生血管性青光眼疗效对比

目的　对比抗VEGF治疗联合微创玻璃体切割、视网膜睫状体光凝术与内窥镜睫状体光凝术(ECP)治疗新生血管性青光眼（neovascular glaucoma,NVG）的疗效。方法　回顾性分析NVG患者49例49眼,分为玻璃体切割联合视网膜睫状体光凝术组（A组）25例25眼和ECP组（B组）24例24眼。观察两组患者术后眼压、视力、虹膜新生血管、术中及术后并发症。结果　两组术后眼压下降,与术前相比差异均有统计学意义（均为P=0.00）。术后2 d、7 d及1个月两组眼压差异均有统计学意义（P=0.00、0.04、0.00）,术后3个月、6个月两组眼压相比差异均无统计学意义（P=0.68、0.59）。末次随访两组视力差异无统计学意义（P=0.64）,较其术前差异均有统计学意义（P=0.04、0.03)。两组患者术后6个月虹膜新生血管消退情况差异有统计学意义（P=0.00）。A组患者术后并发症主要有前房反应性渗出、前房积血,B组患者术中并发症为前房出血,早期并发症有短期内高眼压、角膜水肿、前房反应性渗出、前房积血。结论　玻璃体切割联合视网膜睫状体光凝术与ECP均能降低NVG患者眼压。玻璃体切割联合视网膜睫状体光凝术后早期降低眼压更有效,并发症少。     

玻璃体切除联合白内障手术治疗55例PDR疗效分析

目的:评价玻璃体切除联合晶状体超声乳化及人工晶状体植入术治疗增生性糖尿病视网膜病变(PDR)的疗效及并发症。方法:回顾性分析55例68眼伴有白内障的PDR患者行玻璃体切除联合晶状体超声乳化及人工晶状体植入术的临床资料,观察术后视力改善程度及术中、术后并发症。结果:术后随访3～24(平均8.5)mo。51眼(75%)术后视力维持或改善,17眼(25%)视力下降,其中无光感6眼(9%);术中并发症为医源性视网膜裂孔15眼(22%);术后并发症:前房炎性反应30眼(44%),玻璃体积血11眼(16%),复发性视网膜脱离3眼(4%),虹膜红变5眼(7%),新生血管性青光眼2眼(3%);31眼(46%)术后需要继续眼内光凝。结论:玻璃体切除联合晶状体超声乳化及人工晶状体植入术治疗PDR,可使大多数患者的视力改善,手术是安全的,手术成功的关键为选择合适的患者,影响术后视力的主要因素为视网膜病变程度。